BEGIN:VCALENDAR VERSION:2.0 PRODID:-//171.67.215.200//NONSGML kigkonsult.se iCalcreator 2.26.9// CALSCALE:GREGORIAN METHOD:PUBLISH X-FROM-URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar X-WR-TIMEZONE:America/Los_Angeles BEGIN:VTIMEZONE TZID:America/Los_Angeles X-LIC-LOCATION:America/Los_Angeles BEGIN:STANDARD DTSTART:20231105T020000 TZOFFSETFROM:-0700 TZOFFSETTO:-0800 RDATE:20241103T020000 TZNAME:PST END:STANDARD BEGIN:DAYLIGHT DTSTART:20240310T020000 TZOFFSETFROM:-0800 TZOFFSETTO:-0700 RDATE:20250309T020000 TZNAME:PDT END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT UID:ai1ec-2677@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:Canary Center CONTACT:Ashley Williams\; ashleylw@stanford.edu\; https://www.earlydetectio nresearch.com/ DESCRIPTION:Cancer Research UK\, OHSU Knight Cancer Institute and the Canar y Center at Stanford\, present the Early Detection of Cancer Conference se ries. The annual Conference brings together experts in early detection fro m multiple disciplines to share ground breaking research and progress in t he field.\nThe Conference is part of a long-term commitment to invest in e arly detection research\, to understand the biology behind early stage can cers\, find new detection and screening methods\, and enhance uptake and a ccuracy of screening.\nThe 2021 conference will take place October 6-8 vir tually. For more information visit the website: http://earlydetectionresea rch.com/\nTickets: https://www.earlydetectionresearch.com/virtual-experien ce/. DTSTART;VALUE=DATE:20211006 DTEND;VALUE=DATE:20211009 LOCATION:Virtual Event SEQUENCE:0 SUMMARY:Early Detection of Cancer Conference URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/early-de tection-of-cancer-conference-2/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/EDx21_300x300-150x150.jpg\;150\;150\;1 \,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-cont ent/uploads/2019/10/EDx21_300x300.jpg\;300\;300\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n
\\nCancer Research UK\, OHSU Knight Cancer Institute and the Canary Center at Stanford\, present the Early Detection of Cancer Conference series. The annual Conference brings together experts in early detection from multiple disciplines to share ground breaking res earch and progress in the field.
\nThe Conference is part of a long- term commitment to invest in early detection research\, to understand the biology behind early stage cancers\, find new detection and screening meth ods\, and enhance uptake and accuracy of screening.
\nThe 20 21 conference will take place October 6-8 virtually. For more information visit the website: http://earlydetectionresearch.com/
\nTickets: https://www.earlydetectionresearch.com/virtual- experience/.
X-TICKETS-URL:https://www.earlydetectionresearch.com/virtual-experience/ END:VEVENT BEGIN:VEVENT UID:ai1ec-1509@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:PHIND\,PHIND Seminar Series CONTACT:Ashley Williams\; ashleylw@stanford.edu DESCRIPTION:PHIND Seminar Series: Impact of the Veterans Affairs National A bdominal Aortic Screening Program\nManuel Garcia-Toca\, M.D.\nClinical Pro fessor of Surgery\nChief\, Division of Vascular Surgery\nSanta Clara Vall ey Medical Center (SCVMC)\n \nOliver O. Aalami\, M.D.\nClinical Associate Professor of Surgery\, Vascular Surgery\nLucile Packard Children’s Hospita l\n \nLocation: Zoom\nWebinar URL: https://stanford.zoom.us/s/98417624095 \nDial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nWebinar ID: 9 84 1762 4095\nPasscode: 111283\n11:00am – 12:00pm Seminar & Discussion\nRS VP Here\n \nABSTRACT\nBackground: The U.S. Federal Government enacted the Screen for Abdominal Aortic Aneurysms Very Efficiently Act in January 2007 . Simultaneously\, the Department of Veterans Affairs (VA) implemented a m ore inclusive AAA screening policy for veteran beneficiaries shortly after wards.\n \nOur study aimed to evaluate the impact of the VA program on AAA detection rate and all-cause mortality compared to a cohort of patients w hose aneurysms were identified by other abdominal imaging.\n \nMethods: We identified veterans with an AAA screening study using the two existing Cu rrent Procedural Terminology (CPT) codes (G0389 and 76706). In the compar ison group\, eligible abdominal imaging studies included ultrasound\, comp uted tomography (CT)\, and magnetic resonance imaging (MRI) queried accord ing to CPT codes between 2001 and 2018.\n \nWe used a difference-in-differ ences regression model to evaluate the change in aneurysm detection rate a nd all-cause mortality five years before and eleven years after the VA imp lemented the screening policy in 2007.\n \nWe calculated survival estimate s after AAA screening or non-screening imaging of patients with or without AAA diagnosis and used multivariate Cox regression model to evaluate mort ality in patients with a positive AAA diagnosis adjusting for patient char acteristics and comorbidities.\n \nResults: We identified 3.9 million vete rans with abdominal imaging\, a total of 303\,664 of whom were coded has h aving an AAA US screening between 2007 and 2018. An AAA diagnosis was made in 4.84% of the screening group vs. 1.3% in the non-screening imaging gro up P DTSTART;TZID=America/Los_Angeles:20210420T110000 DTEND;TZID=America/Los_Angeles:20210420T120000 LOCATION:Zoom - See Description for Zoom Link SEQUENCE:0 SUMMARY:PHIND Seminar – Manuel Garcia-Toca\, M.D. & Oliver O. Aalami\, M.D. URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/phind-se minar-manuel-garcia-toca-m-d-oliver-o-aalami-m-d/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/2020.4_SpeakerMashUp_V2-01-150x150.png \;150\;150\;1\,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radcal endar/wp-content/uploads/2019/10/2020.4_SpeakerMashUp_V2-01-300x150.png\;3 00\;150\;1\,large\;http://web.stanford.edu/group/radweb/cgi-bin/radcalenda r/wp-content/uploads/2019/10/2020.4_SpeakerMashUp_V2-01-1024x513.png\;640\ ;321\;1\,full\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp -content/uploads/2019/10/2020.4_SpeakerMashUp_V2-01.png\;1050\;526\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nPHIND Seminar Serie s: Impact of the Veterans Affairs National Abdominal Aortic Screening Program
\nManuel Garcia-Toca\, M.D.
\nClinical Profe
ssor of Surgery
\nChief\, Division of Vascular Surgery
\nSanta
Clara Valley Medical Center (SCVMC)
\n
Oliver O. Aalami\, M.D.
\nClinical Associate Professor of Surgery\, Vascular Surgery
\nLucile Packard Children’s Hospital
\n
Location: Zoom
\nWebinar URL: https://stanford.zoom.us/s/98417624095
\nDi
al: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
\nWebinar ID:
984 1762 4095
\nPasscode: 111283
11:00am – 12:00pm Seminar &
Discussion
\nRSVP Here
\n
Background: The U.S. Federal Government enacted the Screen for Abdominal Aortic Aneurysms Very Efficie ntly Act in January 2007. Simultaneously\, the Department of Veterans Affa irs (VA) implemented a more inclusive AAA screening policy for veteran ben eficiaries shortly afterwards.
\n\n
Our study aimed to evalua te the impact of the VA program on AAA detection rate and all-cause mortal ity compared to a cohort of patients whose aneurysms were identified by ot her abdominal imaging.
\n\n
Methods: We iden tified veterans with an AAA screening study using the two existing Cur rent Procedural Terminology (CPT) codes (G0389 and 76706). In the co mparison group\, eligible abdominal imaging studies included ultrasound\, computed tomography (CT)\, and magnetic resonance imaging (MRI) queried ac cording to CPT codes between 2001 and 2018.
\n\n
We used a di fference-in-differences regression model to evaluate the change in aneurys m detection rate and all-cause mortality five years before and eleven year s after the VA implemented the screening policy in 2007.
\n\n
We calculated survival estimates after AAA screening or non-screening ima ging of patients with or without AAA diagnosis and used multivariate Cox r egression model to evaluate mortality in patients with a positive AAA diag nosis adjusting for patient characteristics and comorbidities.
\np>\n
Results: We identified 3.9 million veterans with a bdominal imaging\, a total of 303\,664 of whom were coded has having an AA A US screening between 2007 and 2018. An AAA diagnosis was made in 4.84% o f the screening group vs. 1.3% in the non-screening imaging group P<0.001\, yet more aneurysms were found with general imaging studies (50\ ,730 vs.15\,449) (Fig 1).
\n\n
On Kaplan-Meier survival analy sis\, patients with an AAA diagnosis had higher overall mortality than pat ients who screened normal\; patients with aneurysms found with non-screeni ng imaging had the highest mortality\, log-rank P<0.001 (Fig 2).< /p>\n
\n
The difference in differences regression analysis\, show ed that the absolute AAA detection rate was 1.55% higher (95% CI 1.2- 1.8) \, and the mortality was 13.89 % lower (95% CI 10.18 %-16.66 %) after the introduction of the screening program in 2007.
\n\n
Multivari ate Cox regression analysis in patients with AAA diagnosis (65-74-year-old ) demonstrated a significantly lower 5-year mortality [HR 0.45 (95% CI 0.4 3-0.48)] for patients in the US Screening group P<0.001.
\n\n
Conclusions: In a nationwide a nalysis of VA patients\, implementation of AAA screening was associated wi th improved survival and a higher rate of AAA diagnosis. These findings pr ovide further support for this program’s continuation versus defaulting to incidental recognition following other abdominal imaging.
\n\n
ABOUT MANUEL GARCIA-TOCA
\nDr. Garcia-Toca earned
his medical degree at the Universidad Anahuac in Mexico 1999. He has a ma
ster’s degree in Health Policy from Stanford University.
\n
He received his general surgery training at the Massachusetts General Hos pital and Brown University in 2008. He then completed a Vascular Surgery f ellowship at Northwestern University in 2010. Dr. Garcia-Toca is board cer tified in both surgery and vascular surgery.
\n\n
Dr. Garcia- Toca joined Stanford Vascular Surgery in 2015. He is currently Clinical Pr ofessor of Surgery in the Division of Vascular Surgery. Dr. Garcia-Toca ha d previously served as an Assistant Professor of Surgery at Brown Universi ty. Dr. Garcia Toca is a Staff Surgeon at Santa Clara Valley Medical Cent er in San Jose.
\n\n
His research interests include new thera peutic strategies and outcomes for the management of vascular trauma\, cer ebrovascular diseases\, dialysis access\, aortic dissection and aneurysms.
\n\n
ABOUT OLIVER O. AALAMI
\nDr. Aala
mi is a Clinical Associate Professor of Vascular & Endovascular Surgery at
Stanford University and the Palo Alto VA and serves as the Lead Director
of Stanford’s Biodesign for Digital Health. He is the course director for
Biodesign for Digital Health\, Building for Digital Health and co-founder
of the open source project\, CardinalKit\, developed to support sensor-b
ased mobile research projects. His primary research focuses on clinically
validating the sensors in smartphones and smartwatches in patients with c
ardiovascular disease to further precision health implementation.
\n
Hosted by: Garry Gold\, M.D.
\nSponsored by th
e PHIND Center and the Department of Radiology
Tickets: https://stanford.zoom.us/we binar/register/8616164417003/WN_5z--vTmvRu6l62kOUd9sZg.
X-TICKETS-URL:https://stanford.zoom.us/webinar/register/8616164417003/WN_5z --vTmvRu6l62kOUd9sZg END:VEVENT BEGIN:VEVENT UID:ai1ec-2417@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:Canary Center\,IBIIS\,MIPS\,PHIND\,Radiology\,RSL CONTACT:Marta Flory\; flory@stanford.edu DESCRIPTION:Targeted violence continues against Black Americans\, Asian Ame ricans\, and all people of color. The department of radiology diversity co mmittee is running a racial equity challenge to raise awareness of systemi c racism\, implicit bias and related issues. Participants will be provided a list of resources on these topics such as articles\, podcasts\, videos\ , etc.\, from which they can choose\, with the “challenge” of engaging wit h one to three media sources prior to our session (some videos are as shor t as a few minutes). Participants will meet in small-group breakout sessio ns to discuss what they’ve learned and share ideas.\nPlease reach out to M arta Flory\, flory@stanford.edu with questions. For details about the sess ion\, including recommended resources and the Zoom link\, please reach out to Meke Faaoso at mfaaoso@stanford.edu.\nTickets: https://docs.google.com /spreadsheets/d/1ehKqHm32peHcm7NQJ427OaKIa9JpfHVunjBk66etZGc/edit?usp=shar ing. DTSTART;TZID=America/Los_Angeles:20210430T120000 DTEND;TZID=America/Los_Angeles:20210430T130000 LOCATION:Zoom SEQUENCE:0 SUMMARY:Racial Equity Challenge: Race in society URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/racial-e quity-challenge-race-in-society/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2021/04/shield-150x150.png\;150\;150\;1\,mediu m\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/upl oads/2021/04/shield.png\;225\;225\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nTargeted violence continues against Black Ameri cans\, Asian Americans\, and all people of color. The department of radiol ogy diversity committee is running a racial equity challenge to raise awar eness of systemic racism\, implicit bias and related issues. Participants will be provided a list of resources on these topics such as articles\, po dcasts\, videos\, etc.\, from which they can choose\, with the “challenge” of engaging with one to three media sources prior to our session (some vi deos are as short as a few minutes). Participants will meet in small-group breakout sessions to discuss what they’ve learned and share ideas.
\n< p>Please reach out to Marta Flory\, fl ory@stanford.edu with questions. For details about the session\, inclu ding recommended resources and the Zoom link\, please reach out to Meke Fa aoso at mfaaoso@stanford.edu.\n X-TICKETS-URL:https://docs.google.com/spreadsheets/d/1ehKqHm32peHcm7NQJ427O aKIa9JpfHVunjBk66etZGc/edit?usp=sharing END:VEVENT BEGIN:VEVENT UID:ai1ec-1757@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:Canary Center\,Early Cancer Detection Seminar Ser ies CONTACT:Ashley Williams\; ashleylw@stanford.edu\; https://canarycenter.stan ford.edu/seminars.html DESCRIPTION:CEDSS: “Building a Scalable Clinical Genomics Program: How tumo r\, normal\, and plasma DNA sequencing are informing cancer care\, cancer risk\, and cancer detection”\n \nMichael Berger\, Ph.D.\nElizabeth and Fel ix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Krav is Center for Molecular Oncology\nMemorial Sloan Kettering Cancer Center\n \nZoom Details\nMeeting URL: https://stanford.zoom.us/s/92559505314\nDial : US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nMeeting ID: 925 595 0 5314\nPasscode: 418727\n11:00am – 12:00pm Seminar & Discussion\nRSVP Her e\n \nABSTRACT\nTumor molecular profiling is a fundamental component of pr ecision oncology\, enabling the identification of oncogenomic mutations th at can be targeted therapeutically. To accelerate enrollment to clinical t rials of molecularly targeted agents and guide treatment selection\, we ha ve established a center-wide\, prospective clinical sequencing program at Memorial Sloan Kettering Cancer Center using a custom\, paired tumor-blood normal sequencing assay (MSK-IMPACT)\, which we have used to profile more than 50\,000 patients with solid tumors. Yet beyond just the characteriza tion of tumor-specific alterations\, the inclusion of blood DNA has readil y enabled the identification of germline risk alleles and somatic mutation s associated with clonal hematopoiesis. To complement this approach\, we h ave also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for cancer detection\, surveillance\, and treatment selection and monitoring. In my talk\, I will describe the prevalence of somatic and germline genomic alte rations in a real-world population\, the clinical benefits of cfDNA assess ment\, and how clonal hematopoiesis can inform cancer risk and confound li quid biopsy approaches to cancer detection.\n \nABOUT\nMichael Berger\, Ph D\, holds the Elizabeth and Felix Rohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Me morial Sloan Kettering Cancer Center\, a multidisciplinary initiative to p romote precision oncology through genomic analysis to guide the diagnosis and treatment of cancer patients. He is also an Associate Attending Geneti cist in the Department of Pathology with expertise in cancer genomics\, co mputational biology\, and high-throughput DNA sequencing technology. His l aboratory is developing experimental and computational methods to characte rize the genetic makeup of individual cancers and identify genomic biomark ers of drug response and resistance. As Scientific Director of Clinical NG S in the Molecular Diagnostics Service\, he oversees the development and b ioinformatics associated with clinical sequencing assays\, and he helped l ead the development and implementation of MSK-IMPACT\, a comprehensive FDA -authorized tumor sequencing panel that been used to profile more than 60\ ,000 tumors from advanced cancer patients at MSK. The resulting data have enabled the characterization of somatic and germline biomarkers across man y cancer types and the identification of mutations associated with clonal hematopoiesis. Dr. Berger also led the development of a clinically validat ed plasma cell-free DNA assay\, MSK-ACCESS\, which his laboratory is using to explore tumor evolution\, acquired drug resistance\, and occult metast atic disease. He received his Bachelor’s Degree in Physics from Princeton University and his Ph.D. in Biophysics from Harvard University.\n \nHosted by: Utkan Demirci\, Ph.D.\nSponsored by: The Canary Center & the Departme nt of Radiology \nStanford University – School of Medicine\nTickets: https ://stanford.zoom.us/webinar/register/5516153318622/WN_MT7TTEciRoWmLVP9GlsJ RA. DTSTART;TZID=America/Los_Angeles:20210511T110000 DTEND;TZID=America/Los_Angeles:20210511T120000 LOCATION:Zoom - See Description for Zoom Link SEQUENCE:0 SUMMARY:Cancer Early Detection Seminar Series – Michael Berger\, Ph.D. URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/cancer-e arly-detection-seminar-series-michael-f-berger-ph-d/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/berger_160204_07-2_3x2-150x150.jpg\;15 0\;150\;1\,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radcalenda r/wp-content/uploads/2019/10/berger_160204_07-2_3x2-300x200.jpg\;300\;200\ ;1\,large\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-con tent/uploads/2019/10/berger_160204_07-2_3x2.jpg\;600\;400\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nCEDSS: “Building a Scalable Clinical Genomics Program: How tumor\, normal\, and plasma DNA se quencing are informing cancer care\, cancer risk\, and cancer detection” em>
\n\n\n
Elizabeth and Fel
ix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Krav
is Center for Molecular Oncology
\nMemorial Sloan Kettering Cancer Ce
nter
\n
Zoom Details
\nMeeti
ng URL: https://stanford.zoom.us/s/92559505314
\nDial: US: +1
650 724 9799 or +1 833 302 1536 (Toll Free)
\nMeeting ID: 925 5950
5314
\nPasscode: 418727
11:00am – 12:00pm Seminar & Discussio
n
\nRSVP Here
\n
ABSTRAC
T
\nTumor molecular profiling is a fundamental component of
precision oncology\, enabling the identification of oncogenomic mutations
that can be targeted therapeutically. To accelerate enrollment to clinical
trials of molecularly targeted agents and guide treatment selection\, we
have established a center-wide\, prospective clinical sequencing program a
t Memorial Sloan Kettering Cancer Center using a custom\, paired tumor-blo
od normal sequencing assay (MSK-IMPACT)\, which we have used to profile mo
re than 50\,000 patients with solid tumors. Yet beyond just the characteri
zation of tumor-specific alterations\, the inclusion of blood DNA has read
ily enabled the identification of germline risk alleles and somatic mutati
ons associated with clonal hematopoiesis. To complement this approach\, we
have also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for canc
er detection\, surveillance\, and treatment selection and monitoring. In m
y talk\, I will describe the prevalence of somatic and germline genomic al
terations in a real-world population\, the clinical benefits of cfDNA asse
ssment\, and how clonal hematopoiesis can inform cancer risk and confound
liquid biopsy approaches to cancer detection.
\n
AB
OUT
\nMichael Berger\, PhD\, holds the Elizabeth and Felix R
ohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kra
vis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Cente
r\, a multidisciplinary initiative to promote precision oncology through g
enomic analysis to guide the diagnosis and treatment of cancer patients. H
e is also an Associate Attending Geneticist in the Department of Pathology
with expertise in cancer genomics\, computational biology\, and high-thro
ughput DNA sequencing technology. His laboratory is developing experimenta
l and computational methods to characterize the genetic makeup of individu
al cancers and identify genomic biomarkers of drug response and resistance
. As Scientific Director of Clinical NGS in the Molecular Diagnostics Serv
ice\, he oversees the development and bioinformatics associated with clini
cal sequencing assays\, and he helped lead the development and implementat
ion of MSK-IMPACT\, a comprehensive FDA-authorized tumor sequencing panel
that been used to profile more than 60\,000 tumors from advanced cancer pa
tients at MSK. The resulting data have enabled the characterization of som
atic and germline biomarkers across many cancer types and the identificati
on of mutations associated with clonal hematopoiesis. Dr. Berger also led
the development of a clinically validated plasma cell-free DNA assay\, MSK
-ACCESS\, which his laboratory is using to explore tumor evolution\, acqui
red drug resistance\, and occult metastatic disease. He received his Bache
lor’s Degree in Physics from Princeton University and his Ph.D. in Biophys
ics from Harvard University.
\n
Hosted by: Utkan Demirc
i\, Ph.D.
\nSponsored by
: The Canary Center & the Department of Radiology
\nStanfor
d University – School of Medicine
Tickets: https://stanford.zoom.us/webinar/registe r/5516153318622/WN_MT7TTEciRoWmLVP9GlsJRA.
X-TICKETS-URL:https://stanford.zoom.us/webinar/register/5516153318622/WN_MT 7TTEciRoWmLVP9GlsJRA END:VEVENT BEGIN:VEVENT UID:ai1ec-2421@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:PHIND\,PHIND Seminar Series CONTACT:Ashley Williams\; ashleylw@stanford.edu DESCRIPTION:PHIND Seminar Series: Multi-Cancer Early Detection Screening Te sts – “Liquid Biopsy Tests” – Are Here – But Will Payers Provide Insurance Coverage?\n \nPatricia A. Deverka\, MD\, MS\, MBE\nExecutive Director\nDe verka Consulting\, LLC\n \nKathryn A. Phillips\, PhD\nProfessor of Health Economics and Health Services Research\nFounding Director\, UCSF Center fo r Translational and Policy Research on Personalized Medicine (TRANSPERS)\n \nLocation: Zoom\nWebinar URL: https://stanford.zoom.us/s/99194110894\nDi al: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nWebinar ID: 991 9 411 0894\nPasscode: 044958\n11:00am – 12:00pm Seminar & Discussion\nRSVP H ere\n \nABSTRACT\nThe emergence of Multi-Cancer Early Detection Screening Tests (MCED) – “liquid biopsy screening tests” – has generated enormous in terest because they could fundamentally shift how cancer screening is done . One company is already offering an MCED test for clinical use as a “lab developed test” (LDT) – and thus addressing the question of “who will pay” has become urgent. These tests offer potentially transformative screening and clinical benefits\, but their characteristics present unique challeng es to payer coverage decision-making and generate concerns about the poten tially high cost of widespread adoption.\nWe will present our ongoing work on examining the unique challenges that MCED present for payer coverage d ecision-making\, drawing on our extensive experience with coverage and rei mbursement for new technologies. We will focus on identifying the evidence generation strategies that could be pursued now to inform payer decision- making so that coverage policies can be developed that are appropriate and equitable for this ground-breaking technology.\n \nABOUT PATRICIA A. DEVE RKA\nDr. Deverka is the Executive Director at Deverka Consulting\, LLC whe re she focuses on helping biotechnology companies and start-ups develop ev idence to support payer coverage and clinical adoption of innovative techn ologies. Her most recent projects have focused on breakthrough tests and drugs focused on population genomic screening\, cancer\, and ultra-rare di sorders. Prior to starting her consulting practice\, Dr. Deverka has work ed in the fields of health economics and outcomes research in both non-pro fit and for-profit settings as a researcher\, educator\, and department he ad. She has extensive experience with patient-centered outcomes research\, drug and diagnostic reimbursement planning\, cost- effectiveness analysis \, and bioethical issues surrounding the use of new technologies. While wo rking in academia and several non-profit firms\, she has participated in n umerous NIH-funded studies to evaluate policy barriers to clinical integra tion of new genomic technologies and has published extensively on strategi es to promote evidence generation and data sharing. She is a member of the National Human Genome Research Institute (NHGRI)’s Genomic Medicine Work Group and serves as a member of NHGRI’s Advisory Council. Deverka has a me dical degree from the University of Pittsburgh and is board certified in G eneral Preventive Medicine and Public Health. She also has a master’s deg ree in bioethics from the University of Pennsylvania and completed a polic y fellowship at Duke University’s Institute for Genome Sciences and Policy .\n \nABOUT KATHRYN A. PHILLIPS\nKathryn A. Phillips founded and leads the UCSF Center for Translational and Policy Research on Personalized Medicin e (TRANSPERS)\, which focuses on developing objective evidence on how to e ffectively\, efficiently\, and equitably implement precision/personalized medicine into health care. Kathryn has published over 150 peer-reviewed ar ticles in major journals including JAMA\, New England Journal of Medicine\ , Science\, and Health Affairs. She has had continuous funding from NIH as a PI for over 25 years and was recently awarded a 5-year NIH grant to exa mine payer coverage and economic value for emerging genomic technologies ( cell-free DNA tests and tests based on polygenic risk scores). Kathryn ser ves on the editorial boards for Health Affairs\, Value in Health\, JAMA In ternal Medicine\, Genetics in Medicine\; is a member of the National Acade my of Medicine Roundtable on Genomics and Precision Health\; and has serve d on the governing Board of Directors for GenomeCanada and as an advisor t o the FDA\, CDC\, and the President’s Council of Advisors on Science and T echnology. She has also served as an advisor to many diagnostics\, sequenc ing\, and pharmaceutical companies. Kathryn is Chair of the Global Economi cs and Evaluation of Clinical Sequencing Working Group\, and a member of a n evidence review committee for the Institute for Clinical and Economic Re view (ICER). \n \n \nHosted by: Garry Gold\, M.D.\nSponsored by the PHIND Center and the Department of Radiology\nTickets: https://stanford.zoom.us /webinar/register/9516200549922/WN_q4_OV6KhRe6MKb_cPEC3GQ. DTSTART;TZID=America/Los_Angeles:20210518T110000 DTEND;TZID=America/Los_Angeles:20210518T120000 LOCATION:Zoom - See Description for Zoom Link SEQUENCE:0 SUMMARY:PHIND Seminar – Patricia A. Deverka\, MD\, MS\, MBE & Kathryn A. Ph illips\, PhD URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/phind-se minar-patricia-a-deverka-md-ms-mbe-kathryn-a-phillips-phd/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/2020.5_SpeakerMashUp-150x126.jpg\;150\ ;126\;1\,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/ wp-content/uploads/2019/10/2020.5_SpeakerMashUp.jpg\;252\;126\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nPHIND Seminar Series: Multi-C ancer Early Detection Screening Tests – “Liquid Biopsy Tests” – Are Here – But Will Payers Provide Insurance Coverage?
\n\n
\nExecutive Director\nDeverka Consulting\, LLC
\n
Kathryn A. Philli
ps\, PhD
\nProfessor of Health Economics and Health Services
Research
\nFounding Director\, UCSF Center for Translational and
Policy Research on Personalized Medicine (TRANSPERS)
\n
Location: Zoom
\nWebinar URL: https://stanford.zoom.us/s/99194
110894
\nDial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free
)
\nWebinar ID: 991 9411 0894
\nPasscode: 044958
11:00am
– 12:00pm Seminar & Discussion
\nRSVP Here
\n
ABSTRACT
\nThe emergence of Multi-Can
cer Early Detection Screening Tests (MCED) – “liquid biopsy screening test
s” – has generated enormous interest because they could fundamentally shif
t how cancer screening is done. One company is already offering an MCED te
st for clinical use as a “lab developed test” (LDT) – and thus addressing
the question of “who will pay” has become urgent. These tests offer potent
ially transformative screening and clinical benefits\, but their character
istics present unique challenges to payer coverage decision-making and gen
erate concerns about the potentially high cost of widespread adoption.
We will present our ongoing work on examining the unique challenges t hat MCED present for payer coverage decision-making\, drawing on our exten sive experience with coverage and reimbursement for new technologies. We w ill focus on identifying the evidence generation strategies that could be pursued now to inform payer decision-making so that coverage policies can be developed that are appropriate and equitable for this ground-breaking t echnology.
\n\n
ABOUT PATRICIA A. DEVERKA
\nDr. Deverka is the Executive Director at Deverka Consulting\, LLC whe
re she focuses on helping biotechnology companies and start-ups develop ev
idence to support payer coverage and clinical adoption of innovative techn
ologies. Her most recent projects have focused on breakthrough tests and
drugs focused on population genomic screening\, cancer\, and ultra-rare di
sorders. Prior to starting her consulting practice\, Dr. Deverka has work
ed in the fields of health economics and outcomes research in both non-pro
fit and for-profit settings as a researcher\, educator\, and department he
ad. She has extensive experience with patient-centered outcomes research\,
drug and diagnostic reimbursement planning\, cost- effectiveness analysis
\, and bioethical issues surrounding the use of new technologies. While wo
rking in academia and several non-profit firms\, she has participated in n
umerous NIH-funded studies to evaluate policy barriers to clinical integra
tion of new genomic technologies and has published extensively on strategi
es to promote evidence generation and data sharing. She is a member of the
National Human Genome Research Institute (NHGRI)’s Genomic Medicine Work
Group and serves as a member of NHGRI’s Advisory Council. Deverka has a me
dical degree from the University of Pittsburgh and is board certified in G
eneral Preventive Medicine and Public Health. She also has a master’s deg
ree in bioethics from the University of Pennsylvania and completed a polic
y fellowship at Duke University’s Institute for Genome Sciences and Policy
.
\n
ABOUT KATHRYN A. PHILLIPS
\nKath
ryn A. Phillips founded and leads the UCSF Center for Translational an
d Policy Research on Personalized Medicine (TRANSPERS)\, which focuse
s on developing objective evidence on how to effectively\, efficiently\, a
nd equitably implement precision/personalized medicine into health care. K
athryn has published over 150 peer-reviewed articles in major journals inc
luding JAMA\, New England Journal of Medicine\, Scie
nce\, and Health Affairs. She has had continuous funding fro
m NIH as a PI for over 25 years and was recently awarded a 5-year NIH gran
t to examine payer coverage and economic value for emerging genomic techno
logies (cell-free DNA tests and tests based on polygenic risk scores). Kat
hryn serves on the editorial boards for Health Affairs\, Valu
e in Health\, JAMA Internal Medicine\, Genetics in Medic
ine\; is a member of the National Academy of Medicine Roundtable on G
enomics and Precision Health\; and has served on the governing Board of Di
rectors for GenomeCanada and as an advisor to the FDA\, CDC\, and the Pres
ident’s Council of Advisors on Science and Technology. She has also served
as an advisor to many diagnostics\, sequencing\, and pharmaceutical compa
nies. Kathryn is Chair of the Global Economics and Evaluation of Clini
cal Sequencing Working Group\, and a member of an evidence review com
mittee for the Institute for Clinical and Economic Review (ICER).
\n
\n
Hosted by: Garry Gold\
, M.D.
\nSponsored by the PHIND Center and the Department of
Radiology
Tickets: https://stanford.zoom.us/webinar/register/9516200549922/WN_q4_O V6KhRe6MKb_cPEC3GQ.
X-TICKETS-URL:https://stanford.zoom.us/webinar/register/9516200549922/WN_q4 _OV6KhRe6MKb_cPEC3GQ END:VEVENT BEGIN:VEVENT UID:ai1ec-1573@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:PHIND\,PHIND Seminar Series CONTACT:Ashley Williams\; ashleylw@stanford.edu DESCRIPTION:PHIND Seminar Series: Pervasive Computing With Everyday Devices To Build & Sustain Resilience & Wellbeing\nPablo E. Paredes\, PhD\nClinic al Assistant Professor\, Psychiatry and Behavioral Sciences and\, by court esy\, Epidemiology and Population Health\nStanford University\n \nZoom Web inar Details\nWebinar URL: https://stanford.zoom.us/s/99098874758\nDial: U S: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nWebinar ID: 990 9887 4 758\nPasscode: 784858\n11:00am – 12:00pm Seminar & Discussion\n12:00pm – 1 2:15pm Reception\nRSVP Here\n \nABSTRACT\nAs society progresses towards in creasing pervasive computing levels\, I design and build technology-enable d solutions to repurpose everyday devices to help people build resilience and grow wellbeing. I leverage biological and behavioral knowledge to desi gn systems that balance user needs and health outcomes while mitigating su rveillance and agency risks. In this talk\, I present my research on effic acious and engaging sensors and interventions necessary in the population and public health domains. I share a series of research projects exploring and validating novel ideas on passive sensors – less dependent on subject ive surveys or wearables – and subtle interventions that minimize workflo w disruption. I show the promise of repurposing existing signals from comp uting peripherals (i.e.\, mouse and trackpad) or cars (steering wheel) int o “sensorless” sensors and repurposing existing media as just-in-time micr o-interventions that can work across multiple scenarios and populations. I discuss how these data could be used in collaboration with domain experts to study topics as varied as the interaction between stress and productiv ity in office workers\, burnout prevention among clinical practitioners\, or the prevention of depression among rural health workers. Finally\, grou nded in theories from neuroscience and behavioral economics\, I propose th e evolution of everyday “mundane” devices\, such as chairs\, desks\, cars\ , or even urban lights\, into adaptive and autonomous wellbeing-optimizing interventions. I close with a discussion of the research needed to system atically study ethics in pervasive technology for resilience\, and wellbei ng.\n \nABOUT\nPablo Paredes earned his Ph.D. in Computer Science from the University of California\, Berkeley\, in 2015 with Prof. John Canny. He i s currently a Clinical Assistant Professor in the Psychiatry and Behaviora l Sciences Department and the Epidemiology and Population Health Departmen t (by courtesy) at the Stanford University School of Medicine. He leads th e Pervasive Wellbeing Technology Lab\, which houses a diverse group of stu dents from multiple departments such as computer science\, electrical engi neering\, mechanical engineering\, anthropology\, neuroscience\, and lingu istics. Before joining the School of Medicine\, Dr. Paredes was a Postdoct oral Researcher in the Computer Science Department at Stanford University with Prof. James Landay. During his Ph.D. career\, he held internships on behavior change and affective computing at Microsoft Research and Google. He has been an active associate editor for the Interactive\, Mobile\, Wire less\, and Ubiquitous Technology Journal (IMWUT) and a reviewer and editor for multiple top CS and medical journals. Before 2010\, he was a senior s trategic manager with Intel in Sao Paulo\, Brazil\, a lead product manager with Telefonica in Quito\, Ecuador\, and an entrepreneur in his native Ec uador and\, more recently\, in the US. In these roles\, he has had the opp ortunity to hire and closely evaluate designers\, engineers\, business peo ple\, and researchers in telecommunications and product development. Durin g his academic career\, Dr. Paredes has advised close to 40 mentees\, incl uding postdocs\, Ph.D.\, master’s\, and undergraduate students\, collabora ted with colleagues from multiple departments across engineering\, medicin e\, and the humanities\, and raised funding from NSF\, NIH\, and large mul tidisciplinary intramural research projects.\n \nHosted by: Garry Gold\, M .D.\nSponsored by the PHIND Center and the Department of Radiology\nTicket s: https://stanford.zoom.us/webinar/register/8316220421859/WN_thRILWbcQK2h 9DllQXNjRQ. DTSTART;TZID=America/Los_Angeles:20210615T110000 DTEND;TZID=America/Los_Angeles:20210615T120000 LOCATION:Zoom - See description for more information SEQUENCE:0 SUMMARY:PHIND Seminar – Pablo E. Paredes\, Ph.D. URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/phind-se minar-pablo-e-paredes-castro-ph-d/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/self_picture_pablo_flowers-150x150.jpe g\;150\;150\;1\,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radca lendar/wp-content/uploads/2019/10/self_picture_pablo_flowers-225x300.jpeg\ ;225\;300\;1\,large\;http://web.stanford.edu/group/radweb/cgi-bin/radcalen dar/wp-content/uploads/2019/10/self_picture_pablo_flowers-768x1024.jpeg\;6 40\;853\;1\,full\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar /wp-content/uploads/2019/10/self_picture_pablo_flowers.jpeg\;2448\;3264\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nPHIND Seminar Seri es: Pervasive Computing With Everyday Devices To Build & Sustain Resil ience & Wellbeing
\nPablo E. Paredes\, PhD
\nClini
cal Assistant Professor\, Psychiatry and Behavioral Sciences and\, by cour
tesy\, Epidemiology and Population Health
\nStanford University
\n
Zoom Webinar Details
\nWebinar
URL: https://stanford.zoom.us/s/99098
874758
\nDial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free
)
\nWebinar ID: 990 9887 4758
\nPasscode: 784858
11:00am
– 12:00pm Seminar & Discussion
\n12:00pm – 12:15pm Reception
\n
RSVP Here
\n
ABSTRACT
\nAs society progresses towards increasing pervasive computing leve
ls\, I design and build technology-enabled solutions to repurpose everyday
devices to help people build resilience and grow wellbeing. I leverage bi
ological and behavioral knowledge to design systems that balance user need
s and health outcomes while mitigating surveillance and agency risks. In t
his talk\, I present my research on efficacious and engaging sensors and i
nterventions necessary in the population and public health domains. I shar
e a series of research projects exploring and validating novel ideas on pa
ssive sensors – less dependent on subjective surveys or wearables – and s
ubtle interventions that minimize workflow disruption. I show the promise
of repurposing existing signals from computing peripherals (i.e.\, mouse a
nd trackpad) or cars (steering wheel) into “sensorless” sensors and repurp
osing existing media as just-in-time micro-interventions that can work acr
oss multiple scenarios and populations. I discuss how these data could be
used in collaboration with domain experts to study topics as varied as the
interaction between stress and productivity in office workers\, burnout p
revention among clinical practitioners\, or the prevention of depression a
mong rural health workers. Finally\, grounded in theories from neuroscienc
e and behavioral economics\, I propose the evolution of everyday “mundane”
devices\, such as chairs\, desks\, cars\, or even urban lights\, into ada
ptive and autonomous wellbeing-optimizing interventions. I close with a di
scussion of the research needed to systematically study ethics in pervasiv
e technology for resilience\, and wellbeing.
\n
ABO
UT
\nPablo Paredes earned his Ph.D. in Computer Science from
the University of California\, Berkeley\, in 2015 with Prof. John Canny.
He is currently a Clinical Assistant Professor in the Psychiatry and Behav
ioral Sciences Department and the Epidemiology and Population Health Depar
tment (by courtesy) at the Stanford University School of Medicine. He lead
s the Pervasive Wellbeing Technology Lab\, which houses a diverse group of
students from multiple departments such as computer science\, electrical
engineering\, mechanical engineering\, anthropology\, neuroscience\, and l
inguistics. Before joining the School of Medicine\, Dr. Paredes was a Post
doctoral Researcher in the Computer Science Department at Stanford Univers
ity with Prof. James Landay. During his Ph.D. career\, he held internships
on behavior change and affective computing at Microsoft Research and Goog
le. He has been an active associate editor for the Interactive\, Mobile\,
Wireless\, and Ubiquitous Technology Journal (IMWUT) and a reviewer and ed
itor for multiple top CS and medical journals. Before 2010\, he was a seni
or strategic manager with Intel in Sao Paulo\, Brazil\, a lead product man
ager with Telefonica in Quito\, Ecuador\, and an entrepreneur in his nativ
e Ecuador and\, more recently\, in the US. In these roles\, he has had the
opportunity to hire and closely evaluate designers\, engineers\, business
people\, and researchers in telecommunications and product development. D
uring his academic career\, Dr. Paredes has advised close to 40 mentees\,
including postdocs\, Ph.D.\, master’s\, and undergraduate students\, colla
borated with colleagues from multiple departments across engineering\, med
icine\, and the humanities\, and raised funding from NSF\, NIH\, and large
multidisciplinary intramural research projects.
\n
Hos
ted by: Garry Gold\, M.D.
\nSponsored by the PHIND Center an
d the Department of Radiology
Tickets: https://stanford.zoom.us/webinar/register/83 16220421859/WN_thRILWbcQK2h9DllQXNjRQ.
X-TICKETS-URL:https://stanford.zoom.us/webinar/register/8316220421859/WN_th RILWbcQK2h9DllQXNjRQ END:VEVENT BEGIN:VEVENT UID:ai1ec-2725@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:PHIND\,PHIND Seminar Series CONTACT:Ashley Williams\; ashleylw@stanford.edu DESCRIPTION:PHIND & CDH Seminar: “The Invisible Future of Health Monitoring ”\nJoin Stanford CDH and PHIND on Wednesday\, June 23rd at 3:15 PM PDT to hear some of the industry’s leading experts talk about embedded sensors\, longitudinal data collection\, the future of remote monitoring\, and real- world applications of precision health technologies. The panel will featur e: Nicolas Genain\, MS\, Withings\; John O Moore MD\, PhD\, Fitbit Health Solutions at Google\; Pablo Paredes\, PhD\, MBA\, MS\, Stanford University \; and Michael Synder\, PhD\, Stanford University. The discussion will be moderated by Jun (Alex) Gao\, MS\, Samsung America.\n \nZoom Webinar Detai ls\nWebinar URL: https://stanford.zoom.us/s/96984014176\nDial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nWebinar ID: 969 8401 4176\nPassc ode: 375941\n3:15pm – 4:15pm: Panel Discussion\nRSVP Here\n \n \nSponsored by the PHIND Center and Center for Digital Health\nTickets: https://stanf ord.zoom.us/webinar/register/7016228432975/WN_7RpA06gIQICRCH6bzQjt3w. DTSTART;TZID=America/Los_Angeles:20210623T151500 DTEND;TZID=America/Los_Angeles:20210623T161500 LOCATION:Zoom - See Description for Zoom Link SEQUENCE:0 SUMMARY:“The Invisible Future of Health Monitoring” – PHIND & CDH Seminar URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/the-invi sible-future-of-health-monitoring-phind-cdh-seminar/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/June-23rd-webinar-external-calendar-ti le-01-150x150.png\;150\;150\;1\,medium\;http://web.stanford.edu/group/radw eb/cgi-bin/radcalendar/wp-content/uploads/2019/10/June-23rd-webinar-extern al-calendar-tile-01-300x205.png\;300\;205\;1\,large\;http://web.stanford.e du/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/June-23rd-w ebinar-external-calendar-tile-01-1024x700.png\;640\;438\;1\,full\;http://w eb.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/1 0/June-23rd-webinar-external-calendar-tile-01.png\;1251\;855\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nPH IND & CDH Seminar: “The Invisible Future of Health Monitoring”
\nJoin Stanford CDH and PHIN D on Wednesday\, June 23rd at 3:15 PM PDT to hear some of the industry ’s leading experts talk about embedded sensors\, longitudinal data collect ion\, the future of remote monitoring\, and real-world applications of pre cision health technologies. The panel will feature: Nicolas G enain\, MS\, Withings\; John O Moore MD\, PhD\, Fitbit Health Solutions at Google a>\; Pablo Paredes\, PhD\, MBA\, MS\, Stanford University\; and Michael Synder\ , PhD\, Stanford University. The discussion will be moderated by Jun (Alex) Gao\, M S\, Samsung America.
\n\n
Zoom Webinar Detail
s
\nWebinar URL: https://stanford.zoom
.us/s/96984014176
\nDial: US: +1 650 724 9799 or +1 833 302 1536
(Toll Free)
\nWebinar ID: 969 8401 4176
\nPasscode: 375941
3:15pm – 4:15pm: Panel Discussion
\nRSVP Here<
/a>
\n
\n
Sponsored by the PHIND Center and Cent er for Digital Health
\nTickets: https://stanford.zoom.us/webinar/register/7016228432 975/WN_7RpA06gIQICRCH6bzQjt3w.
X-TICKETS-URL:https://stanford.zoom.us/webinar/register/7016228432975/WN_7R pA06gIQICRCH6bzQjt3w END:VEVENT BEGIN:VEVENT UID:ai1ec-2803@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:AIMI\,IBIIS\,Radiology\,RSL CONTACT: DESCRIPTION:Radiology Department-Wide Research Meeting\n• Research Announce ments\n• Mirabela Rusu\, PhD – Learning MRI Signatures of Aggressive Prost ate Cancer: Bridging the Gap between Digital Pathologists and Digital Radi ologists\n• Akshay Chaudhari\, PhD – Data-Efficient Machine Learning for M edical Imaging\nLocation: Zoom – Details can be found here: https://radres earch.stanford.edu\nMeetings will be the 3rd Friday of each month.\n \nHos ted by: Kawin Setsompop\, PhD\nSponsored by: the the Department of Radiolo gy DTSTART;TZID=America/Los_Angeles:20210716T120000 DTEND;TZID=America/Los_Angeles:20210716T130000 LOCATION:Zoom – Details can be found here: https://radresearch.stanford.edu SEQUENCE:0 SUMMARY:Radiology-Wide Research Conference URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/radiolog y-wide-research-conference/ X-COST-TYPE:free X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2021/07/RWRC-July-150x150.jpeg\;150\;150\;1\,m edium\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content /uploads/2021/07/RWRC-July-300x195.jpeg\;300\;195\;1\,large\;http://web.st anford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2021/07/RWR C-July.jpeg\;443\;288\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nRadiology Department-Wide Research Meeting
\n•
Research Announcements
\n• Mirabela Rusu\, PhD – Learning MRI Signat
ures of Aggressive Prostate Cancer: Bridging the Gap between Digital Patho
logists and Digital Radiologists
\n• Akshay Chaudhari\, PhD – Data-Ef
ficient Machine Learning for Medical Imaging
Location: Zoom – Details can be found here: https://radresearch.st
anford.edu
\nMeetings will be the 3rd Friday of each month.
\n
Hosted by: Kawin Setsompop\, PhD
\nSponsore
d by: the the Department of Radiology
PHIND Seminar Seri es: Plastic-based sensors for wearable technologies: fundamentals and applications
\n\n
Alberto Salleo\, Ph.D.
\nProfes
sor of Material Sciences and Engineering
\nStanford University
Zoom Webinar Details
\nWebinar
URL: https://stanford.zoom.us/s/92646686705
\nDial: US: +1 65
0 724 9799 or +1 833 302 1536 (Toll Free)
\nWebinar ID: 926 4668 670
5
\nPasscode: 270341
11:00am – 12:00pm Seminar & Discussion\nRSVP Here
\n\n
ABSTRACT
strong>
\nThe continuous monitoring of human health can greatly benef
it from devices that can be worn comfortably or seamlessly integrated in h
ousehold objects\, constituting “health-centered” domotics. One of the key
aspects for these devices to be successful is to be invisibly integrated
and disappear in the background of our lives. Our group works on thin film
devices made with plastic materials that can be used for electrochemicall
y sensing of common analytes from easily accessible bodily fluids (e.g. sw
eat\, saliva\, urine) and can be easily multiplexed. I will describe elect
rochemical transistors that detect ionic species either directly present i
n body fluids or resulting from a selective enzymatic reaction (e.g. ammon
ia from creatinine) at physiological levels. I will also show that non-cha
rged molecules can be detected by making use of custom-processed polymer m
embranes that act as “synthetic enzymes”. Using these membranes in conjunc
tion with electrochemical transistors we demonstrate that we are able to m
easure physiological levels of cortisol in real human sweat. Importantly\,
transistors can amplify signals and I will show what architectures must b
e used to observe 1000x amplification of sensing currents.
Finally we have developed a process that allows us to fabricate sensor arrays on flexible substrates thereby opening the door towards ultra-thin\, flexible sensor arrays for wearable technologies.
\n\n
ABOUT<
/strong>
\nAlberto Salleo is currently Full Professor of Materials Sc
ience and Department Chair at Stanford University. Alberto Salleo holds a
Laurea degree in Chemistry from La Sapienza and graduate
d as a Fulbright Fellow with a PhD in Materials Science from UC Berkeley i
n 2001. From 2001 to 2005 Salleo was first post-doctoral research fellow a
nd successively member of research staff at Xerox Palo Alto Research Cente
r. In 2005 Salleo joined the Materials Science and Engineering Department
at Stanford as an Assistant Professor in 2006. Salleo is a Principal Edito
r of MRS Communications since 2011.While at Stanford\, Salleo won the NSF
Career Award\, the 3M Untenured Faculty Award\, the SPIE Early Career Awar
d\, the Tau Beta Pi Excellence in Undergraduate Teaching Award\, and the G
ores Award for Excellence in Teaching\, Stanford’s highest teaching award.
He has been a Thomson Reuters Highly Cited Researcher since 2015
\, recognizing that he ranks in the top 1% cited researchers in his field.
\n
Hosted by: Garry Gold\, M.D.
\nSponso
red by the PHIND Center and the Department of Radiology
Ticke ts: https://stanford.z oom.us/webinar/register/2816249009305/WN_lUezgp98RMKzD7rC6oeRFg.
BODY> X-TICKETS-URL:https://stanford.zoom.us/webinar/register/2816249009305/WN_lU ezgp98RMKzD7rC6oeRFg END:VEVENT BEGIN:VEVENT UID:ai1ec-1619@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:PHIND\,PHIND Seminar Series CONTACT:Ashley Williams\; ashleylw@stanford.edu\; https://med.stanford.edu/ phind/events/2021.html DESCRIPTION:PHIND Seminar Series: Peace of mind for those affected by strok e\nOrestis Vardoulis\, Ph.D.\nCo-Founder & CEO\nZeitMedical\n \nZoom Webin ar Details\nWebinar URL: https://stanford.zoom.us/s/94427469356\nDial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nWebinar ID: 944 2746 935 6\nPasscode: 999031\n11:00am – 12:00pm Seminar & Discussion\n12:00pm – 12: 15pm Reception\nRSVP Here\n \nABSTRACT\nThere is a growing population of o ver 10 million Americans that live with an elevated risk of having a strok e.\nEach year approximately 1 million Americans survive a stroke or a mini stroke\, often severely affected by its debilitating effects. A more disab ling stroke frequently occurs after the seminal events\, leaving patients and their families scarred for life.\nTIME = BRAIN. Early hospital present ation is the most critical determinant in good stroke outcomes. However\, most patients arrive at the hospital often hours after the event\, with le ss than 10% receiving any form of treatment (thrombolysis / thrombectomy). \nAs a result\, at risk individuals struggle daily with the fear\, a strok e might happen during night-time or when they are alone. Unfortunately a s troke that goes unnoticed for hours\, is most often not treatable due to t he lack of salvageable tissue.\nTo alleviate that fear\, we are creating a n AI-powered\, smart-headband that analyzes brain waves to detect the onse t of an event immediately\, and alert the patient\, caregivers and 911.\nO ur stroke detection AI has already been shown to detect ischemia during hi gh-risk surgeries with 90% sensitivity and no false positives.\nWe have re ceived FDA breakthrough designation for our solution and are currently run ning a pilot human factors and signal quality study.\nOur vision is to pro vide peace of mind and optimal brain health for everyone.\n \nABOUT\nOrest is is the CEO and Co-founder of Zeit Medical\, a telehealth company that o ffers at home monitoring and alert solutions for patients at risk for stro ke. Prior to starting Zeit\, Orestis was a Stanford Biodesign Innovation F ellow where his team developed the initial idea about at-home stroke detec tion. Orestis trained as a Mechanical Engineer\, at Aristotle University\, Greece\, earned his PhD in Biotechnology and Bioengineering at EPFL\, Swi tzerland and conducted cutting edge research in flexible wearable electron ics with the Bao Group at Stanford Chemical Engineering. He has authored m ore than twenty publications in prestigious journals and has filed for a v ariety of patents at the intersection of materials technology and medical devices. Orestis currently lives in San Francisco\, where he also contribu tes to the UCSF-Stanford pediatric device consortium as a technology advis or. He also maintains close ties with the med-tech and health-tech commun ities in Switzerland and Greece\, contributing to regional Biodesign educa tional workshops.\n \nHosted by: Garry Gold\, M.D.\nSponsored by the PHIND Center and the Department of Radiology\nTickets: https://stanford.zoom.us /webinar/register/3016264733187/WN_i3dqwzHERYOfa7-Y87t7PQ. DTSTART;TZID=America/Los_Angeles:20210817T110000 DTEND;TZID=America/Los_Angeles:20210817T120000 LOCATION:Zoom - See Description for Zoom Link SEQUENCE:0 SUMMARY:PHIND Seminar – Orestis Vardoulis\, Ph.D. URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/phind-se minar-orestis-vardoulis-ph-d/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/ovardoulis_hshot_1-150x150.png\;150\;1 50\;1\,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp -content/uploads/2019/10/ovardoulis_hshot_1-300x300.png\;300\;300\;1\,larg e\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/upl oads/2019/10/ovardoulis_hshot_1.png\;640\;640\;\,full\;http://web.stanford .edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/ovardouli s_hshot_1.png\;716\;716\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nPHIND Seminar Series: P eace of mind for those affected by stroke
\nOrestis Vardoulis\, Ph.D.
strong>
\nCo-Founder & CEO
\nZeitMedical
\n
<
em>Zoom Webinar Details
\nWebinar URL: http
s://stanford.zoom.us/s/94427469356
\nDial: US: +1 650 724 9799 o
r +1 833 302 1536 (Toll Free)
\nWebinar ID: 944 2746 9356
\nPass
code: 999031
11:00am – 12:00pm Seminar & Discussion
\n12:00pm
– 12:15pm Reception
\nRSVP Here
\n
ABSTRACT
\nThere is a growing population of ov er 10 million Americans that live with an elevated risk of having a stroke .
\nEach year approximately 1 million Americans survive a stroke or a ministroke\, often severely affected by its debilitating effects. A more disabling stroke frequently occurs after the seminal events\, leaving pat ients and their families scarred for life.
\nTIME = BRAIN. Early hos pital presentation is the most critical determinant in good stroke outcome s. However\, most patients arrive at the hospital often hours after the ev ent\, with less than 10% receiving any form of treatment (thrombolysis / t hrombectomy).
\nAs a result\, at risk individuals struggle daily wit h the fear\, a stroke might happen during night-time or when they are alon e. Unfortunately a stroke that goes unnoticed for hours\, is most often no t treatable due to the lack of salvageable tissue.
\nTo alleviate th at fear\, we are creating an AI-powered\, smart-headband that analyzes bra in waves to detect the onset of an event immediately\, and alert the patie nt\, caregivers and 911.
\nOur stroke detection AI has already been shown to detect ischemia during high-risk surgeries with 90% sensitivity a nd no false positives.
\nWe have received FDA breakthrough designati on for our solution and are currently running a pilot human factors and si gnal quality study.
\nOur vision is to provide peace of mind and opt imal brain health for everyone.
\n\n
ABOUT\nOrestis is the CEO and Co-founder of Zeit Medical\, a telehealth com pany that offers at home monitoring and alert solutions for patients at ri sk for stroke. Prior to starting Zeit\, Orestis was a Stanford Biodesign I nnovation Fellow where his team developed the initial idea about at-home s troke detection. Orestis trained as a Mechanical Engineer\, at Aristotle U niversity\, Greece\, earned his PhD in Biotechnology and Bioengineering at EPFL\, Switzerland and conducted cutting edge research in flexible wearab le electronics with the Bao Group at Stanford Chemical Engineering. He has authored more than twenty publications in prestigious journals and has fi led for a variety of patents at the intersection of materials technology a nd medical devices. Orestis currently lives in San Francisco\, where he al so contributes to the UCSF-Stanford pediatric device consortium as a techn ology advisor. He also maintains close ties with the med-tech and health- tech communities in Switzerland and Greece\, contributing to regional Biod esign educational workshops.
\n\n
Hosted by: Garry Gold\,
M.D.
\nSponsored by the PHIND Center and the Department of
Radiology
Tickets: https://stanford.zoom.us/webinar/register/3016264733187/WN_i3dqw zHERYOfa7-Y87t7PQ.
X-TICKETS-URL:https://stanford.zoom.us/webinar/register/3016264733187/WN_i3 dqwzHERYOfa7-Y87t7PQ END:VEVENT BEGIN:VEVENT UID:ai1ec-1645@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:PHIND\,PHIND Seminar Series CONTACT:Ashley Williams\; ashleylw@stanford.edu DESCRIPTION:PHIND Seminar Series: Towards precision diagnostic and predicti on of food allergy\nSindy KY Tang\, Ph.D.\nAssociate Professor of Mechanic al Engineering\, Senior Fellow at the Woods Institute for the Environment and Professor\, by courtesy\, of Radiology – PHIND Center\nStanford Univer sity\n \nLocation: Zoom\nWebinar URL: https://stanford.zoom.us/s/919329663 34\nDial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nWebinar ID: 919 3296 6334\nPasscode: 383071\n11:00am – 12:00pm Seminar & Discussion\n RSVP Here\n \nABSTRACT\nFood allergy has reached epidemic proportions. Acc urate in vitro methods that are efficient and easy to use to identify offe nding food allergens are lacking. Oral food challenge\, the gold standard for food allergy assessment\, is often not performed as it places the pati ent at risk of anaphylaxis. As such\, food allergy is often identified onl y after an adverse reaction that could be life-threatening. Our long-term goal is to develop a food allergy diagnostic test that is accurate\, safe\ , rapid\, and accessible\, so that food allergy can be easily identified p rior to the occurrence of an adverse reaction\, and that the efficacy of i mmunotherapy for food allergy can be tracked more effectively. This talk w ill discuss our recent work on developing such a test. Our approach is bas ed on the Basophil Activation Test (BAT)\, which measures the activation o f basophils in whole blood after stimulation with specific food allergens ex vivo. The BAT has been shown to be highly predictive of allergic reacti ons. However\, the need for flow cytometry has limited its broader use. We are developing a miniaturized\, standalone version of the BAT. We envisio n that the test can be used at the point of care\, such as the doctor’s of fice or at a local pharmacy.\n \nABOUT\nProf. Sindy KY Tang is the Kenneth and Barbara Oshman Faculty Scholar and Associate Professor of Mechanical Engineering and by courtesy of Radiology (Precision Health and Integrated Diagnostics) at Stanford University. She received her Ph.D. from Harvard U niversity in Engineering Sciences under the supervision of Prof. George Wh itesides. Her lab at Stanford works on the fundamental understanding of fl uid mechanics and mass transport in micro-nano systems\, and the applicati on of this knowledge towards problems in biology\, rapid diagnostics for h ealth and environmental sustainability. The current areas of focus include the flow physics of confined micro-droplets using experimental and machin e learning methods\, interfacial mass transport and self-assembly\, and ul trahigh throughput opto-microfluidic systems for disease diagnostics\, wat er and energy sustainability\, and single-cell wound healing studies. She was a Stanford Biodesign Faculty Fellow in 2018. Dr. Tang’s work has been recognized by multiple awards including the NSF CAREER Award\, 3M Nontenur ed Faculty Award\, the ACS Petroleum Fund New Investigator Award\, and inv ited lecture at the Nobel Symposium on Microfluidics in Sweden. Website: h ttp://web.stanford.edu/group/tanglab/\n \nHosted by: Garry Gold\, M.D.\nSp onsored by the PHIND Center and the Department of Radiology\nTickets: http s://stanford.zoom.us/webinar/register/1216286302579/WN_3iFMsumAT9iKlV5G1Vr 9zA. DTSTART;TZID=America/Los_Angeles:20210921T110000 DTEND;TZID=America/Los_Angeles:20210921T120000 LOCATION:Zoom - See Description for Zoom Link SEQUENCE:0 SUMMARY:PHIND Seminar – Sindy KY Tang\, Ph.D. URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/phind-se minar-sindy-ky-tang-ph-d/ X-COST-TYPE:external X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/sindy-tang_profilephoto-150x150.jpg\;1 50\;150\;1\,medium\;http://web.stanford.edu/group/radweb/cgi-bin/radcalend ar/wp-content/uploads/2019/10/sindy-tang_profilephoto-300x300.jpg\;300\;30 0\;1\,large\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-c ontent/uploads/2019/10/sindy-tang_profilephoto.jpg\;350\;350\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nPHIND Seminar Series: Towards precision diagnostic and prediction of food allergy
\nSindy KY Tan
g\, Ph.D.
\nAssociate Professor of Mechanical Engineerin
g\, Senior Fellow at the Woods Institute for the Environment and Professor
\, by courtesy\, of Radiology – PHIND Center
\nStanford University
\n
Location: Zoom
\nWebinar URL: https://stanford.zoom.us/s/91932966334
\nDial: US: +1
650 724 9799 or +1 833 302 1536 (Toll Free)
\nWebinar ID: 919 3296 6
334
\nPasscode: 383071
11:00am – 12:00pm Seminar & Discussion
\nRSVP Here
\n
ABSTRACT
\nFood allergy has reached epidemic proportions. Accurate i
n vitro methods that are efficient and easy to use to identify offending f
ood allergens are lacking. Oral food challenge\, the gold standard for foo
d allergy assessment\, is often not performed as it places the patient at
risk of anaphylaxis. As such\, food allergy is often identified only after
an adverse reaction that could be life-threatening. Our long-term goal is
to develop a food allergy diagnostic test that is accurate\, safe\, rapid
\, and accessible\, so that food allergy can be easily identified prior to
the occurrence of an adverse reaction\, and that the efficacy of immunoth
erapy for food allergy can be tracked more effectively. This talk will dis
cuss our recent work on developing such a test. Our approach is based on t
he Basophil Activation Test (BAT)\, which measures the activation of basop
hils in whole blood after stimulation with specific food allergens ex vivo
. The BAT has been shown to be highly predictive of allergic reactions. Ho
wever\, the need for flow cytometry has limited its broader use. We are de
veloping a miniaturized\, standalone version of the BAT. We envision that
the test can be used at the point of care\, such as the doctor’s office or
at a local pharmacy.
\n
ABOUT
\nProf
. Sindy KY Tang is the Kenneth and Barbara Oshman Faculty Scholar and Asso
ciate Professor of Mechanical Engineering and by courtesy of Radiology (Pr
ecision Health and Integrated Diagnostics) at Stanford University. She rec
eived her Ph.D. from Harvard University in Engineering Sciences under the
supervision of Prof. George Whitesides. Her lab at Stanford works on the f
undamental understanding of fluid mechanics and mass transport in micro-na
no systems\, and the application of this knowledge towards problems in bio
logy\, rapid diagnostics for health and environmental sustainability. The
current areas of focus include the flow physics of confined micro-droplets
using experimental and machine learning methods\, interfacial mass transp
ort and self-assembly\, and ultrahigh throughput opto-microfluidic systems
for disease diagnostics\, water and energy sustainability\, and single-ce
ll wound healing studies. She was a Stanford Biodesign Faculty Fellow in 2
018. Dr. Tang’s work has been recognized by multiple awards including the
NSF CAREER Award\, 3M Nontenured Faculty Award\, the ACS Petroleum Fund Ne
w Investigator Award\, and invited lecture at the Nobel Symposium on Micro
fluidics in Sweden. Website: http://web.stanford.edu/group/tanglab/
\n
Hoste
d by: Garry Gold\, M.D.
\nSponsored by the PHIND Center and
the Department of Radiology
Tickets: https://stanford.zoom.us/webinar/register/1216 286302579/WN_3iFMsumAT9iKlV5G1Vr9zA.
X-TICKETS-URL:https://stanford.zoom.us/webinar/register/1216286302579/WN_3i FMsumAT9iKlV5G1Vr9zA END:VEVENT BEGIN:VEVENT UID:ai1ec-2295@web.stanford.edu/group/radweb/cgi-bin/radcalendar DTSTAMP:20240330T031151Z CATEGORIES;LANGUAGE=en-US:Canary Center\,Early Cancer Detection Seminar Ser ies CONTACT:Ashley Williams\; ashleylw@stanford.edu\; https://canarycenter.stan ford.edu/seminars.html DESCRIPTION:CEDSS: The First Cell: A new model for cancer research and trea tment\nAzra Raza\, M.D.\nChan Soon-Shiong Professor of Medicine\nDirector\ , Myelodysplastic Syndrome Center\nColumbia University Medical Center\n \n Location: Zoom\nMeeting URL: https://stanford.zoom.us/s/99340345860\nDial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)\nMeeting ID: 993 4034 5860\nPasscode: 711508\nRSVP Here\n \nABSTRACT\nCancer research continues to be predicated on a 1970’s model of research and treatment. Despite hal f a century of intense research\, we are failing spectacularly to improve the outcome for patients with advanced disease. Those who are cured contin ue to be treated mostly with the older strategies (surgery-chemo-radiation ). Our contention is that the real solution to the cancer problem is to di agnose cancer early\, at the stage of The First Cell. The rapidly evolving technologies are doing much in this area but need to be expanded. We stud y a pre-leukemic condition called myelodysplastic syndrome (MDS) with the hope that we can detect the first leukemia cells as the disease transforms to acute myeloid leukemia (AML). Towards this end\, we have collected blo od and bone marrow samples on MDS and AML patients since 1984. Today\, our Tissue Repository has more than 60\,000 samples. We propose novel methods to identify surrogate markers that can identify the First Cell through st udying the serial samples of patients who evolve from MDS to AML.\n \nABOU T\nDr. Raza is a Professor of Medicine and Director of the MDS Center at C olumbia University in New York\, NY.She started her research in Myelodispl astic Syndromes (MDS) in 1982 and moved to Rush University\, Chicago\, Ill inois in 1992\, where she was the Charles Arthur Weaver Professor in Oncol ogy and Director\, Division of Myeloid Diseases. The MDS Program\, along w ith a Tissue Repository containing more than 50\,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Ma ssachusetts in 2004 and to Columbia University in 2010.\nBefore moving to New York\, Dr. Raza was the Chief of Hematology Oncology and the Gladys Sm ith Martin Professor of Oncology at the University of Massachussetts in Wo rcester. She has published the results of her laboratory research and clin ical trials in prestigious\, peer reviewed journals such as The New Englan d Journal of Medicine\, Nature\, Blood\, Cancer\, Cancer Research\, Britis h Journal of Hematology\, Leukemia\, and Leukemia Research. Dr. Raza serve s on numerous national and international panels as a reviewer\, consultant and advisor and is the recipient of a number of awards.\n \nHosted by: Ut kan Demirci\, Ph.D.\nSponsored by: The Canary Center & the Department of R adiology \nStanford University – School of Medicine DTSTART;TZID=America/Los_Angeles:20211012T110000 DTEND;TZID=America/Los_Angeles:20211012T120000 LOCATION:Venue coming soon! SEQUENCE:0 SUMMARY:Cancer Early Detection Seminar Series – Azra Raza\, MD URL:http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/event/cancer-e arly-detection-seminar-series-azra-raza-md/ X-COST-TYPE:free X-WP-IMAGES-URL:thumbnail\;http://web.stanford.edu/group/radweb/cgi-bin/rad calendar/wp-content/uploads/2019/10/A_Raza-150x150.png\;150\;150\;1\,mediu m\;http://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/upl oads/2019/10/A_Raza-300x200.png\;300\;200\;1\,large\;http://web.stanford.e du/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/A_Raza.png\ ;640\;426\;\,full\;http://web.stanford.edu/group/radweb/cgi-bin/radcalenda r/wp-content/uploads/2019/10/A_Raza.png\;700\;466\; X-ALT-DESC;FMTTYPE=text/html:\\n\\n\\nCEDSS: The First Cell: A new model for cancer research and treatment
\nAzra Raza\, M.D.
\nChan
Soon-Shiong Professor of Medicine
\nDirector\, Myelodysplastic Syndro
me Center
\nColumbia University Medical Center
\n
L
ocation: Zoom
\nMeeting URL: https:
//stanford.zoom.us/s/99340345860
\nDial: US: +1 650 724 9799 or
+1 833 302 1536 (Toll Free)
\nMeeting ID: 993 4034 5860
\nPassco
de: 711508
ABSTRACT
\nCancer research continues to be predicated on a 1970’s model of research and treatment. Despite half a century of intense research\, we are failing spectacularly to improve the outcome for patients with advanced disease. Those who are cured continue to be treated mostly with the older strategies (surgery-chemo-radiation). Our contention is that the real solution to the cancer problem is to diagn ose cancer early\, at the stage of The First Cell. The rapidly evolving te chnologies are doing much in this area but need to be expanded. We study a pre-leukemic condition called myelodysplastic syndrome (MDS) with the hop e that we can detect the first leukemia cells as the disease transforms to acute myeloid leukemia (AML). Towards this end\, we have collected blood and bone marrow samples on MDS and AML patients since 1984. Today\, our Ti ssue Repository has more than 60\,000 samples. We propose novel methods to identify surrogate markers that can identify the First Cell through study ing the serial samples of patients who evolve from MDS to AML.
\np>\n
ABOUT
\nDr. Raza is a Professor of Medicine and Director of the MDS Center at Columbia University in New York\, NY.She started her research in Myelodisplastic Syndromes (MDS) in 1982 and moved to Rush University\, Chicago\, Illinois in 1992\, where she was the Charl es Arthur Weaver Professor in Oncology and Director\, Division of Myeloid Diseases. The MDS Program\, along with a Tissue Repository containing more than 50\,000 samples from MDS and acute leukemia patients was successfull y relocated to the University of Massachusetts in 2004 and to Columbia Uni versity in 2010.
\nBefore moving to New York\, Dr. Raza was the Chie f of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachussetts in Worcester. She has published the r esults of her laboratory research and clinical trials in prestigious\, pee r reviewed journals such as The New England Journal of Medicine\, Nature\, Blood\, Cancer\, Cancer Research\, British Journal of Hematology\, Leukem ia\, and Leukemia Research. Dr. Raza serves on numerous national and inter national panels as a reviewer\, consultant and advisor and is the recipien t of a number of awards.
\n\n
Hosted by: Utkan Demirci\,
Ph.D.
\nSponsored by: Th
e Canary Center & the Department of Radiology
\nStanford Un
iversity – School of Medicine
PHIND Seminar Series: Top ic TBA
\nChristina Curtis\, Ph.D.
\nAssociate Professor of
Medicine (Oncology) and of Genetics
\nStanford University
p>\n
Location: Venue coming soon!
\n11:00am – 12:00pm Seminar & Dis
cussion
\n12:00pm – 12:15pm Reception
\nRSVP coming soon!
ABSTRACT
\nComing soon!
\n< p>ABOUT
\n
Hosted
by: Garry Gold\, M.D.
\nSponsored by the PHIND Center and th
e Department of Radiology
PHIND Seminar Series: Male Infertility and the Future Risk of Vascular and CV Disease
\n<
a href='https://profiles.stanford.edu/michael-eisenberg'>Michael E
isenberg\, M.D.
\nAssociate Professor of Urology and\, b
y courtesy\, of Obstetrics and Gynecology
\nStanford University Medic
al Center
\n
Gary M. Shaw\, Ph.D.
\nNICU Nurses Professor
and Professor\, by courtesy\, of Health Research and Policy (Epidemiology
) and of Obstetrics and Gynecology (Maternal Fetal Medicine)
\nStanfo
rd University
\n
Location: Venue coming soon!
\n11:00a
m – 12:00pm Seminar & Discussion
\n12:00pm – 12:15pm Reception
\nRSVP coming soon!
\n
ABSTRACT
\nCom
ing soon!
\n
ABOUT
\nComing soon!
\n
Hosted by: Garry Gold\, M.D.
\nSponsored
by the PHIND Center and the Department of Radiology